We measured the protein expression of ASCL1, NEUROD1, POU2F3, and YAP1 by immunohistochemistry in 286 SCLC patients of the CHCAMS cohort, and then classified these SCLC patients into one of four subtypes based on the predominant expression of four transcription factors. This evidence concerns the gene YAP1 and small cell lung carcinoma.